NeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Monday. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Up 0.5 %

Shares of NeuroMetrix stock opened at $3.96 on Monday. The firm has a market cap of $8.09 million, a PE ratio of -0.86 and a beta of 2.18. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The business’s fifty day simple moving average is $4.00 and its 200-day simple moving average is $3.85.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The company had revenue of $0.59 million for the quarter. During the same quarter last year, the business posted ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.